US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily S&P Biotech Bull 3x Shares

169.89

+11.427.21%

Post-market: 169.890.00000.00%16:01 EDT

Volume:823.10K

Turnover:134.48M

Market Cap:547.81M

PE:- -

High:171.45

Open:157.00

Low:156.80

Close:158.47

52wk High:198.18

52wk Low:32.55

Shares:3.22M

Float Shares:3.22M

Volume Ratio:0.98

T/O Rate:25.53%

Dividend:1.33

Dividend Rate:0.78%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Xenon’s Azetukalner Hits Phase 3 Mark in Focal Onset Seizures, Paving Way for FDA Filing

Trevi Therapeutics completes End-of-Phase 2 meeting with FDA

ImmunityBio resubmits sBLA to FDA for Anktiva plus BCG

Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough

Press Release: Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

Why Is uniQure Stock Skyrocketing Monday?

Benzinga_recent_news

Press Release: enGene Reports First Quarter 2026 Financial Results and Provides Business Update

Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Hims & Hers Health (HIMS) and Regeneron (REGN)

Analysts Have Conflicting Sentiments on These Healthcare Companies: Roche Holding AG (OtherRHHVF), Incyte (INCY) and Oncology Institute (TOI)

Metropolis Healthcare Shareholders Approve Bonus Share Issue via E-Voting

Incyte Says FDA Declines Supplemental Biologics Application for Zynyz Injection

MT Newswires Live

Bristol-Myers Squibb Says Psoriatic Arthritis Medication Sotyktu Received FDA Approval

MT Newswires Live

Kunlun Health Insurance Shanghai Branch Advances Consumer Protection Initiatives with 2026 "3·15" Campaign

Barclays Sticks to Their Buy Rating for Bayer (0P6S)

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Ardent Health Partners, Inc. (ARDT) and Caribou Biosciences (CRBU)

Vicore Pharma Targets Investor Visibility With Back-to-Back Healthcare Conferences

Analysts Offer Insights on Healthcare Companies: OmniAb (OABI) and Cresco Labs (OtherCRLBF)

AB&B BIO-TECH-B Surges Over 7% in Late Trading on Inclusion in Stock Connect and FDA Clearance for Monkeypox Vaccine

Lupin Gets Two Observations from US FDA After Ankleshwar Facility Inspection

MT Newswires Live

Analysts Conflicted on These Healthcare Names: Biohaven Ltd. (BHVN) and Atai Beckley N.V. (ATAI)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LABU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"Direxion Daily S&P Biotech Bull 3x Shares","latestPrice":169.89,"timestamp":1773086400000,"preClose":158.47,"halted":0,"volume":823101,"hourTrading":{"tag":"盘后","latestPrice":169.89,"preClose":169.89,"latestTime":"16:01 EDT","volume":123,"amount":20896.469999999998,"timestamp":1773086492921,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.07206411308134024,"floatShares":3224486,"shares":3224486,"eps":0,"marketStatus":"Post-Mkt","change":11.42,"latestTime":"03-09 16:02:44 EDT","open":157,"high":171.45,"low":156.8,"amount":134482406.27106002,"amplitude":0.092447,"askPrice":170.4,"askSize":200,"bidPrice":168.6,"bidSize":200,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1773100800000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":158.47,"sharesOutstanding":3074486,"nav":158.249,"aum":510272375.11,"dividendRate":0.007835,"bidAskSpread":0.002103,"preHourTrading":{"tag":"盘前","latestPrice":157.86,"preClose":158.47,"latestTime":"09:29 EDT","volume":4353,"amount":669547.33605,"timestamp":1773062999999,"change":-0.61,"changeRate":-0.003849,"amplitude":0.045876},"postHourTrading":{"tag":"盘后","latestPrice":169.89,"preClose":169.89,"latestTime":"16:01 EDT","volume":123,"amount":20896.469999999998,"timestamp":1773086492921,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.97709,"impliedVol":1.0552,"impliedVolPercentile":0.8924},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":3224486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.97709,"shares":3224486,"dividePrice":1.3311,"high":171.45,"amplitude":0.092447,"preClose":158.47,"low":156.8,"week52Low":32.55,"pbRate":"--","week52High":198.18,"institutionHeld":0,"latestPrice":169.89,"eps":0,"divideRate":0.007835,"volume":823101,"delay":0,"ttmEps":0,"open":157,"prevYearClose":159.39,"prevWeekClose":158.47,"prevMonthClose":172.7,"prevQuarterClose":159.39,"fiveDayClose":169.5,"twentyDayClose":166.47,"sixtyDayClose":157.87},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2618359625","title":"Xenon’s Azetukalner Hits Phase 3 Mark in Focal Onset Seizures, Paving Way for FDA Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2618359625","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618359625?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:58","pubTimestamp":1773057533,"startTime":"0","endTime":"0","summary":"Xenon ( ($XENE) ) just unveiled an update. Xenon Pharmaceuticals reported positive topline results from its Phase 3 X-TOLE2 trial of azetukalner in...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/xenons-azetukalner-hits-phase-3-mark-in-focal-onset-seizures-paving-way-for-fda-filing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/xenons-azetukalner-hits-phase-3-mark-in-focal-onset-seizures-paving-way-for-fda-filing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","LABU"],"gpt_icon":0},{"id":"2618623620","title":"Trevi Therapeutics completes End-of-Phase 2 meeting with FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2618623620","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618623620?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:41","pubTimestamp":1773056468,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics (TRVI) announced the results of its End-of-Phase 2 meeting with the U.S. Food and Drug Administration, FDA. At the meeting, the ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/trevi-therapeutics-completes-end-of-phase-2-meeting-with-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/trevi-therapeutics-completes-end-of-phase-2-meeting-with-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","TRVI","LABU","LENZ","BK4585","BK4139","BK4539","BK4007"],"gpt_icon":0},{"id":"2618623935","title":"ImmunityBio resubmits sBLA to FDA for Anktiva plus BCG","url":"https://stock-news.laohu8.com/highlight/detail?id=2618623935","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618623935?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:35","pubTimestamp":1773056138,"startTime":"0","endTime":"0","summary":"ImmunityBio (IBRX) announced that the U.S. FDA has acknowledged receipt of its supplemental Biologics License Application for Anktiva plus Bacillus...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immunitybio-resubmits-sbla-to-fda-for-anktiva-plus-bcg-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immunitybio-resubmits-sbla-to-fda-for-anktiva-plus-bcg-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LABU","IBRX","BCG","BK4139","BK4135","BK4588"],"gpt_icon":0},{"id":"2618238886","title":"Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough","url":"https://stock-news.laohu8.com/highlight/detail?id=2618238886","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618238886?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:30","pubTimestamp":1773055800,"startTime":"0","endTime":"0","summary":"The Company will conduct two Phase 3 clinical trials of nalbuphine ER for the treatment of patients with IPF-related chronic cough First pivotal trial is on track to initiate in the second quarter of ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/09/3251724/0/en/Trevi-Therapeutics-Announces-Completion-of-End-of-Phase-2-Meeting-with-the-FDA-Gaining-Alignment-for-Its-Development-Program-for-Idiopathic-Pulmonary-Fibrosis-Related-Chronic-Cough.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LABU","LENZ","RCC","BK4588","BK4539","BK4585","BK4007"],"gpt_icon":0},{"id":"2618064076","title":"Press Release: Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2618064076","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618064076?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:05","pubTimestamp":1773054300,"startTime":"0","endTime":"0","summary":"Following Positive Type B Meetings with the FDA, BLA Submission for TA-ERT for the Treatment of Sanfilippo Syndrome Type B  on Track for the Fourth Quarter of 2026. Appoints Dale Hooks as Chief Commercial Officer, Strengthening the Company's Commercial Capabilities in Preparation for a Potential Launch of TA-ERT. Secured up to $50 Million in Growth Capital from Avenue Capital Group. Spruce Biosciences, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2025 and provided corporate updates.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0052756011.USD","LABU","SG9999001440.SGD","LU0072461881.USD","LU0128525689.USD","BK4175","LU0792757196.USD","BK4585","BK4139","LU1571399168.USD","PA3.SI","LU0310799852.SGD","LU1880398554.USD","LU1880398471.USD","LU0310800965.SGD","BK4604","LU0211327993.USD","LU1267930490.SGD","LU0006061336.USD","CAH","LU0211328371.USD","LU1267930813.SGD","TM","BK4555","LU0889566641.SGD","LU0162691827.USD","LU1267930227.SGD","LU0154236417.USD","03160","BK4588","SPRB","BK4099","BK6045","BK6512"],"gpt_icon":0},{"id":"2618590628","title":"Why Is uniQure Stock Skyrocketing Monday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2618590628","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618590628?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:01","pubTimestamp":1773054060,"startTime":"0","endTime":"0","summary":"uniQure (QURE) stock surges following news of CBER director Vinay Prasad's exit. See why the market is reacting so strongly.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/09/FDA-Flags-Possible-Listeria-Contaminatio.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/09/FDA-Flags-Possible-Listeria-Contaminatio.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/26/03/51122452/why-is-uniqure-stock-skyrocketing-monday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/03/51122452/why-is-uniqure-stock-skyrocketing-monday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU0320765992.SGD","LU0109394709.USD","BK4139","BK4585","LABU","LU0889565916.HKD","QURE","BK4588"],"gpt_icon":0},{"id":"2618640488","title":"Press Release: enGene Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2618640488","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618640488?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:00","pubTimestamp":1773054000,"startTime":"0","endTime":"0","summary":"LEGEND pivotal cohort update planned for a spring 2026 medical conference. 12-month complete response data from LEGEND pivotal cohort expected in 2H 2026. Biologics License Application  submission for detalimogene planned for 2H 2026. Cash and marketable securities of $312.5 million expected to provide cash runway into 2H 2028. enGene Holdings Inc. , a clinical-stage, non-viral genetic medicines company, today announced its financial results for the first quarter ended January 31, 2026, and provided a business update.\"As data from LEGEND's pivotal cohort in high-risk, BCG-unresponsive NMIBC continues to mature, we look forward to providing an update at a spring medical conference,\" said Ron Cooper, President and Chief Executive Officer, enGene. \"On the heels of our successful November follow-on offering, we entered 2026 in a position of financial strength and ready to execute. With RMAT and CDRP designations for detalimogene, we are in active dialogue with the FDA to ensure regulatory ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BHPRN162.USD","BK4161","BK4139","LU0267386448.USD","LU2746668974.SGD","IE00BFXG1179.USD","LU0882574139.USD","BK4022","TRAE","DDX","CMC","HTGC","BK4585","BCG","LU2237443465.HKD","LU2746668461.USD","IE00B1BXHZ80.USD","LU0971096721.USD","LU0149725797.USD","LU0170899867.USD","LU1363072403.SGD","LABU","LU2237443549.SGD","LU2237443978.SGD","BK4232","LU2237443895.HKD","CR","ENGN","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU2237443382.USD","BK4588","BK4006","LU2237443622.USD","BK4135","R"],"gpt_icon":0},{"id":"2618664014","title":"Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Hims & Hers Health (HIMS) and Regeneron (REGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618664014","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618664014?lang=en_us&edition=fundamental","pubTime":"2026-03-09 18:50","pubTimestamp":1773053412,"startTime":"0","endTime":"0","summary":"Analysts fell to the sidelines weighing in on Exelixis (EXEL – Research Report), Hims & Hers Health (HIMS – Research Report) and Regeneron (REGN – ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-exelixis-exel-hims-hers-health-hims-and-regeneron-regn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-exelixis-exel-hims-hers-health-hims-and-regeneron-regn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1974910355.USD","EXEL","LU0289739699.SGD","LU2106854487.HKD","BK4585","LU2023250504.SGD","BK4196","LU0882574055.USD","LU2468319806.SGD","XBI","BK4139","LABU","BK4532","REGN","HIMZ","LU2089984988.USD","LU0053666078.USD","LU0058720904.USD","LU0029874061.USD","LU0889565916.HKD","BK4581","LU0114720955.EUR","HIMS","BK4588","LU0320765992.SGD","LU2362541513.USD","LU0823434740.USD","LU0823434583.USD","LU1917777945.USD","LU2362540622.SGD","HIMY","LU0128526141.USD","BK4137","LU2237438978.USD","HIYY","LU2362541273.HKD","HMYY","LU0109394709.USD","LU0823416689.USD"],"gpt_icon":0},{"id":"2618647470","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Roche Holding AG (OtherRHHVF), Incyte (INCY) and Oncology Institute (TOI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618647470","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618647470?lang=en_us&edition=fundamental","pubTime":"2026-03-09 18:40","pubTimestamp":1773052830,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Roche Holding AG (RHHVF – Research Report), Incyte...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-roche-holding-ag-otherrhhvf-incyte-incy-and-oncology-institute-toi-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-roche-holding-ag-otherrhhvf-incyte-incy-and-oncology-institute-toi-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","AG","BK4550","HCSG","BK4137","BK4585","LU0128526141.USD","BK4581","INCY","XBI","XLV","LU0029874061.USD","TOI","BK4139","BK4210","BK4588","BK4185","BK4532"],"gpt_icon":0},{"id":"2618647471","title":"Metropolis Healthcare Shareholders Approve Bonus Share Issue via E-Voting","url":"https://stock-news.laohu8.com/highlight/detail?id=2618647471","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618647471?lang=en_us&edition=fundamental","pubTime":"2026-03-09 18:36","pubTimestamp":1773052606,"startTime":"0","endTime":"0","summary":"An update from Metropolis Healthcare Ltd. ( ($IN:METROPOLIS) ) is now available. Metropolis Healthcare has secured shareholder approval via a posta...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/metropolis-healthcare-shareholders-approve-bonus-share-issue-via-e-voting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/metropolis-healthcare-shareholders-approve-bonus-share-issue-via-e-voting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","XBI","XLV","HCSG","LU0128526141.USD","BK4588","BK4581","BK4585","LABU","BK4137"],"gpt_icon":0},{"id":"2618647578","title":"Incyte Says FDA Declines Supplemental Biologics Application for Zynyz Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2618647578","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618647578?lang=en_us&edition=fundamental","pubTime":"2026-03-09 18:29","pubTimestamp":1773052186,"startTime":"0","endTime":"0","summary":"Incyte  said in a Friday filing that the US Food and Drug Administration did not approve the supplemental biologics application for an additional indication of its Zynyz injection for the treatment of adult patients with metastatic non-small cell lung cancer, combined with platinum-based chemotherapy.The company said a Feb. 27 complete response letter from the FDA cited certain inspection findings related to Catalent Indiana, the third-party fill-finish facility in the application, as the \"sole approvability issue.\"Catalent Indiana is a part of Novo Nordisk and Incyte said it is working with the facility and the FDA to address the matter. The FDA's letter did not cite any other concern in the application, the company added.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0154236417.USD","IE00BZ1G4Q59.USD","BK4588","LABU","NVOX","BK4007","NVOH","BK4599","BK4585","LU1093756168.USD","LU1093756325.SGD","BK4139","INCY","BK4550","NVO","IE00BKVL7J92.USD","BK4532"],"gpt_icon":0},{"id":"2618440816","title":"Bristol-Myers Squibb Says Psoriatic Arthritis Medication Sotyktu Received FDA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2618440816","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618440816?lang=en_us&edition=fundamental","pubTime":"2026-03-09 17:54","pubTimestamp":1773050073,"startTime":"0","endTime":"0","summary":"Bristol-Myers Squibb  said late Friday its Sotyktu inhibitor has received approval from the US Food and Drug Administration to treat adults with active psoriatic arthritis.The company said that the approval is based on results from its POETYK PsA-1 and POETYK PsA-2 trials, which evaluated the efficacy and safety of a 6 mg once-daily dose of Sotyktu in patients with active psoriatic arthritis.In both trials, treatment with Sotyktu met its primary endpoint and key secondary endpoints, the company said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1868837136.USD","LU1261432733.SGD","BK4534","LU0868494617.USD","LU1868836914.USD","LU0225284248.USD","LU1074936037.SGD","LU2242652126.USD","LU0061475181.USD","LU1868836591.USD","LABU","LU0882574055.USD","BK4532","LU1670711040.USD","LU1323610961.USD","IE00B2B36J28.USD","LU1430594728.SGD","BK4588","LU2125154935.USD","LU0114720955.EUR","LU1571399168.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","LU1868837300.USD","IE00BSNM7G36.USD","LU0321505439.SGD","LU1291159041.SGD","LU1989771016.USD","BK4585","LU2125154778.USD","IE00BFXG1179.USD","LU1093756325.SGD","LU1670711123.USD","LU1670710588.SGD","LU1868836757.USD","BMY","LU2360032135.SGD","BK4007","LU1883839398.USD","LU2242646821.SGD","LU0267386448.USD","LU0237698245.USD","LU0306806265.USD","LU2133065610.SGD","BK4581","LU1670710661.SGD","LU0096364046.USD","LU0306807586.USD","LU0456855351.SGD","LU0225771236.USD"],"gpt_icon":0},{"id":"1172352180","title":"Kunlun Health Insurance Shanghai Branch Advances Consumer Protection Initiatives with 2026 \"3·15\" Campaign","url":"https://stock-news.laohu8.com/highlight/detail?id=1172352180","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172352180?lang=en_us&edition=fundamental","pubTime":"2026-03-09 17:02","pubTimestamp":1773046934,"startTime":"0","endTime":"0","summary":"In anticipation of the 2026 \"3·15\" International Consumer Rights Day, Kunlun Health Insurance Shanghai Branch has proactively launched a series of consumer protection awareness activities. Centered...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4581","XBI","XLV","LABU"],"gpt_icon":0},{"id":"2618645047","title":"Barclays Sticks to Their Buy Rating for Bayer (0P6S)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618645047","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618645047?lang=en_us&edition=fundamental","pubTime":"2026-03-09 16:05","pubTimestamp":1773043556,"startTime":"0","endTime":"0","summary":"Barclays analyst Charles Pitman CFA maintained a Buy rating on Bayer today and set a price target of €48.00. Pitman CFA covers the Healthcare secto...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-their-buy-rating-for-bayer-0p6s-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-their-buy-rating-for-bayer-0p6s-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","XLV","BK4585","XBI","BK4588","LABU","CFA"],"gpt_icon":0},{"id":"2618645397","title":"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Ardent Health Partners, Inc. (ARDT) and Caribou Biosciences (CRBU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618645397","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618645397?lang=en_us&edition=fundamental","pubTime":"2026-03-09 16:01","pubTimestamp":1773043312,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Eli Lilly & Co (LLY – Research Report), Ardent Hea...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-ardent-health-partners-inc-ardt-and-caribou-biosciences-crbu-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-ardent-health-partners-inc-ardt-and-caribou-biosciences-crbu-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1974910355.USD","LLY","LU1280957306.USD","LU2087625088.SGD","LU0234572021.USD","BK4516","LU2168564495.EUR","LU2106854487.HKD","LU0225283273.USD","SGXZ99366536.SGD","LU0353189680.USD","SG9999014898.SGD","SG9999015945.SGD","ARDT","LU2552382058.USD","LU0106261372.USD","LU0323591593.USD","LU1064131342.USD","LU2361044949.HKD","IE00B4R5TH58.HKD","LU1712237335.SGD","LU1267930730.SGD","IE00B7KXQ091.USD","LU0158827948.USD","LU0964807845.USD","LU1983299246.USD","LU2491049909.HKD","LU2746668461.USD","BK4588","LU0006306889.USD","LU2417539215.USD","LU1868836591.USD","LU0079474960.USD","LU1868837136.USD","SG9999015952.SGD","SG9999018857.SGD","IE00BK4W5M84.HKD","LU1061106388.HKD","LU2357305700.SGD","LU2471134879.HKD","LU0061475181.USD","IE00BKDWB100.SGD","LU2602419157.SGD","LU0823434583.USD","LU2237443978.SGD","LU0353189763.USD","LU0203201768.USD","LU1069344957.HKD","IE00BJLML261.HKD","LU1551013425.SGD","LU2750360641.GBP","LU0456855351.SGD","LU1551013342.USD","LU0289739699.SGD","BK4585","IE00B2B36J28.USD","IE00B775H168.HKD","LU0708995401.HKD","IE00BK4W5L77.USD","LU2468319806.SGD","XBI","LU2168564065.EUR","IE00BKPKM429.USD","LU1868836914.USD","LU0256863811.USD","LU1868837300.USD","LU0058720904.USD","SG9999001176.SGD","BK4534","IE00B4JS1V06.HKD","IE00BFSS7M15.SGD","BK4581","LU0471298694.HKD","LU1145028129.USD","BK4599","LU2111349929.HKD","LU1093756325.SGD","BK4007","LU1720051017.SGD","LU2265009873.SGD","LU1804176565.USD","LU1868836757.USD","IE00BJJMRY28.SGD","LU1917777945.USD","LU2108987350.USD","LU2271345857.HKD","LU2491050154.USD","LU2461242641.AUD","SGXZ81514606.USD","LU0097036916.USD","LLYX","LU0158827781.USD","SG9999014914.USD","LU0820561818.USD","BK4137","LU2361045086.USD","LU0203202063.USD","ELIS","GB00BDT5M118.USD","LU2168563687.JPY","LU0320765059.SGD","LU0122379950.USD","LU2023251221.USD","LU0820561909.HKD","LU2089284900.SGD","LU2456880835.USD","SGXZ51526630.SGD","LU0354030511.USD","LU0354030438.USD","LU0417517546.SGD","SG9999001176.USD","LU0787776722.HKD","IE00BFTCPJ56.SGD","LU0109391861.USD","LU1127390331.HKD","LU2471134523.USD","LU0882574055.USD","LU0672654240.SGD","LU0316494557.USD","LU2213496289.HKD","LU0094547139.USD","CRBU","LU0256863902.USD","LU1035775433.USD","BK4533","LU0689472784.USD","LU2236285917.USD","LU2237443382.USD","LU2023250330.USD","LU2063271972.USD","IE00BFSS8Q28.SGD","LU2746668974.SGD","LU2756315664.SGD","LU0114720955.EUR","LU2237443895.HKD","LU0385154629.USD","SGXZ57979304.SGD","LU0683600562.USD","IE0004445239.USD","LU0320765992.SGD","IE0005OL40V9.USD","LU2237443465.HKD","LU0210536198.USD","SG9999015986.USD","LU0432979614.USD","LU0128526141.USD","LU1023059063.AUD","ELIL","LU1366192091.USD","LU2237443549.SGD","LU2264538146.SGD","LU1989771016.USD","IE00BJJMRZ35.SGD","LU2896262040.SGD","IE00BJT1NW94.SGD","LU0109394709.USD","LU2462157665.USD","LU0823416689.USD","LLYZ","LU0198837287.USD","IE00BJJMRX11.SGD","LU2552382132.HKD","LLII","LU2552382215.SGD","LU2324357040.USD","BK4539","LU1988902786.USD","LU1232071149.USD","IE0002141913.USD","IE0009355771.USD","LU2023250504.SGD","LU2360106947.USD","LU2491050071.SGD","SG9999013999.USD","LU0786609619.USD","LU1093756168.USD","LU2168564149.EUR","BK4139","LABU","LU2361044865.SGD","LU0238689110.USD","LU0471298777.SGD","SG9999017495.SGD","LU2089984988.USD","LU2089283258.USD","LU1548497426.USD","LU1623119135.USD","LU1814569148.SGD","IE0001KFT4U8.USD","LU2756315318.SGD","SG9999018865.SGD","LU1629891620.HKD","LU0029874061.USD","LU0889565916.HKD","IE00B1XK9C88.USD","LU2168564222.USD","LU2028103732.USD","IE0004445015.USD","LU2471134952.CNY","SG9999015978.USD","LU0943347566.SGD","LU2112291526.USD","LU0882574139.USD","LU1323610961.USD","LU2211815571.USD","LU0266013472.USD","LU1720051108.HKD","LU2750360997.AUD","LU0823434740.USD","LU1291159041.SGD","SG9999014906.USD","SGXZ31699556.SGD","LU1057294990.SGD","LU2471134796.USD","LU0640476718.USD","BK4185","SG9999014880.SGD","LU0466842654.USD","LU2237443622.USD","LU2237438978.USD","IE00BN29S564.USD","LU0096364046.USD","LU0820562030.AUD","IE00BWXC8680.SGD","IE00B1BXHZ80.USD"],"gpt_icon":0},{"id":"2618645372","title":"Vicore Pharma Targets Investor Visibility With Back-to-Back Healthcare Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2618645372","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618645372?lang=en_us&edition=fundamental","pubTime":"2026-03-09 15:42","pubTimestamp":1773042130,"startTime":"0","endTime":"0","summary":"Vicore Pharma Holding AB ( ($SE:VICO) ) just unveiled an update. Vicore Pharma Holding AB will showcase its clinical-stage portfolio of angiotensin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vicore-pharma-targets-investor-visibility-with-back-to-back-healthcare-conferences?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vicore-pharma-targets-investor-visibility-with-back-to-back-healthcare-conferences?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","LU2065170008.USD","LU1770036033.HKD","SG9999006266.SGD","SG9999014492.USD","BK4085","BK4548","LU0823038988.USD","SG9999002620.SGD","LU1861220207.SGD","LU0348788117.USD","SG9999002679.SGD","LU1048588211.SGD","BK4581","LU0979878070.USD","BK4137","BK4551","IE0001KFT4U8.USD","LU0589944569.HKD","IE0031814969.USD","SG9999002414.USD","LU0264606111.USD","BK4554","LU0516422366.SGD","LU0210637038.USD","BK4588","BK4585","SG9999014484.SGD","LU2008162690.USD","LU2125910849.SGD","LU0072462343.USD","LU0516422952.EUR","LU0175139822.USD","LU2543165471.USD","LU0572940350.SGD","IE0034224299.USD","BK4566","LU2045819591.USD","LU0499858602.USD","IE00BD6J9T35.USD","LU0289960550.SGD","SG9999005177.SGD","BK4503","LABU","SG9999013486.USD","SG9999004360.SGD","LU0128526141.USD","LU0572939691.SGD","LU0532188223.SGD","LU2152927971.USD","LU0441851309.USD","LU0737861269.HKD","LU1242518857.USD","LU1839390173.USD","SG9999001135.SGD","LU0251143029.SGD","LU1242518931.SGD","LU0261945553.USD","LU2238330802.EUR","LU0516422440.USD","LU0516423091.SGD","BK4535","LU0823039010.USD","LU2360107671.USD","LU0029874061.USD","LU2065171402.SGD","LU2177674079.SGD","LU2065169927.USD","SGXZ58947870.SGD","LU0499858438.USD","BK4220","LU1861217088.USD","LU2125910500.SGD","LU0048573645.USD","LU0345776255.USD","SG9999002604.SGD","LU2065171311.SGD","SG9999013478.USD","LU0516423174.USD","SG9999002406.SGD","SG9999013460.SGD","LU0345775950.USD"],"gpt_icon":0},{"id":"2618645398","title":"Analysts Offer Insights on Healthcare Companies: OmniAb (OABI) and Cresco Labs (OtherCRLBF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618645398","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618645398?lang=en_us&edition=fundamental","pubTime":"2026-03-09 15:40","pubTimestamp":1773042028,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on OmniAb (OABI – Research Report) and Cresco Labs (CRL...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-omniab-oabi-and-cresco-labs-othercrlbf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-omniab-oabi-and-cresco-labs-othercrlbf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","LABU","HCSG","LU0128526141.USD","BK4121","BK4588","LU0029874061.USD","BK4585","XBI","XLV","BK4581","OABI"],"gpt_icon":0},{"id":"1146910619","title":"AB&B BIO-TECH-B Surges Over 7% in Late Trading on Inclusion in Stock Connect and FDA Clearance for Monkeypox Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1146910619","media":"Stock News","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146910619?lang=en_us&edition=fundamental","pubTime":"2026-03-09 15:25","pubTimestamp":1773041110,"startTime":"0","endTime":"0","summary":"AB&B BIO-TECH-B (02627) saw its shares rise more than 7% during the late trading session. At the time of writing, the stock was up 7.31%, trading at HK$56.5, with a turnover of HK$87.528 million. The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627","BK4585","BK4588","159646","LABU","BK1161","VXUS"],"gpt_icon":0},{"id":"2618617336","title":"Lupin Gets Two Observations from US FDA After Ankleshwar Facility Inspection","url":"https://stock-news.laohu8.com/highlight/detail?id=2618617336","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618617336?lang=en_us&edition=fundamental","pubTime":"2026-03-09 14:21","pubTimestamp":1773037311,"startTime":"0","endTime":"0","summary":"Lupin  has received two observations from the US Food and Drug Administration  after the inspection of its manufacturing facility in Ankleshwar, India, according to a filing to the stock exchanges on Saturday.Shares of the company fell over 2% in Monday's trade.The inspection was carried out by the regulator from March 2 to March 7.The company stated that it will address the observations and respond to the US FDA within the given timeframe.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LABU","BK4588","BK4585"],"gpt_icon":0},{"id":"2618113086","title":"Analysts Conflicted on These Healthcare Names: Biohaven Ltd. (BHVN) and Atai Beckley N.V. (ATAI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618113086","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618113086?lang=en_us&edition=fundamental","pubTime":"2026-03-09 11:40","pubTimestamp":1773027620,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biohaven Ltd. (BHVN – Research Report) and Atai Beckley N.V. (ATA...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-biohaven-ltd-bhvn-and-atai-beckley-n-v-atai-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-biohaven-ltd-bhvn-and-atai-beckley-n-v-atai-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU0128526141.USD","XLV","BK4539","BK4585","LU1093756168.USD","LABU","LU1093756325.SGD","BHVN","ATAI","BK4007","BK4137","BK4581","LU0029874061.USD","HCSG","XBI","BK4588"],"gpt_icon":0}],"pageSize":20,"totalPage":22,"pageCount":2,"totalSize":430,"code":"91000000","status":"200"}]}}